Human Microbiome-based Drugs and Diagnostics: Global Markets
The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024.
The human microbiome-based drugs constitute 95% of this market and should reach $9.3 billion in sales by 2024.
The size of the microbiome diagnostics market is expected to remain modest at $543.8 million in 2024.
The human microbiome-based drugs constitute 95% of this market and should reach $9.3 billion in sales by 2024.
The size of the microbiome diagnostics market is expected to remain modest at $543.8 million in 2024.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MICROBIOME OVERVIEW
Scientific Background
Human Microbiome in Health and Disease
Advances in Microbiome Research
Focus Areas for Microbiome-Based Drugs and Diagnostics
Microbiome-Based Drugs: Product Development Strategies
Current Challenges in Microbiome Drug Development
Human Microbiome Project
MetaHIT Consortium
Public Sector Initiatives in Microbiome Research
Key Goals of the Human Microbiome Project
Key Achievements of the Human Microbiome Project
Key Goals of MetaHIT Initiative
CHAPTER 4 HUMAN MICROBIOME-BASED DRUGS MARKET
Cancer
Obesity
Type 2 Diabetes
Ulcerative Colitis and Crohn's Disease
Clostridium Difficle Infection
Lactose Intolerance
Dental caries
Recurrent Bacterial Vaginosis and Urinary Tract Infection
Skin Diseases
Hyperoxaluria
Urea Cycle Disorder
Celiac Disease
Phenylketonuria
Non-alcoholic Steatohepatitis (NASH)
Background
Microbiome and Cancer
Microbiome-based Drugs for Cancer: Review of Drugs in Development
Market for Microbiome-based Drugs for Cancer
Background
Microbiome and Obesity
Microbiome-based Drugs for Obesity: Review of Drugs in Development
Market for Microbiome-based Drugs for Obesity
Background
Microbiome and Type 2 Diabetes
Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development
Market for Microbiome-based Drugs for Type 2 Diabetes
Background
Microbiome and Ulcerative Colitis/Crohn's Disease
Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs in Development
Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease
Background
Microbiome and Clostridium Difficle Infection
Microbiome-based Drugs for Clostridium Difficle Infection: Review of Drugs in Development
Market for Microbiome-based Drugs for Clostridium Difficle Infection
Background
Microbiome and Lactose Intolerance
Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development
Market for Microbiome-based Product for Lactose Intolerance
Background
Microbiome and Dental Caries
Microbiome-based Drugs for Dental Caries Review of Drugs in Development
Market for Microbiome-based Products for Dental Caries
Background
Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection
Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs in Development
Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI
Background
Microbiome and Skin Diseases
Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development
Market for Microbiome-based Drugs for Skin Diseases
Background
Microbiome and Hyperoxaluria
Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development
Market for Microbiome-based Products for Hyperoxaluria
Background
Microbiome and Urea Cycle Disorder
Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development
Market for Microbiome-Based Drugs for Urea Cycle Disorder
Background
Microbiome and Celiac Disease
Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development
Market for Microbiome-based Products for Celiac Disease
Background
Microbiome and Phenylketonuria
Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development
Market for Microbiome-based Products for Phenylketonuria
Background
Microbiome and Non-alcoholic Steatohepatitis
Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in Development
Market for Microbiome-based Products for Non-alcoholic Steatohepatitis
Microbiome-based Products for Hepatic Encephalopathy
Microbiome and Hepatic Encephalopathy
Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development
Market for Microbiome-based Drugs for Hepatic Encephalopathy
Drug Development Strategies
Microbiome-Based Drugs as Immune System Activators
Microbiome-Based Drugs as an Add-on to Immuno-Oncology Drugs
Microbiome-Based Drugs as Probiotic Mixtures
Microbiome-Based Drugs as Chemotherapy Adjuncts
Microbiome-Based Drugs in Development for Cancer
Micabodies (AvidBiotics)
Oncobiotics (Evelo Biosciences)
SER-155 (Seres Therapeutics)
Symberix Compound (Symberix)
MRX581 (4D Pharma)
AG-013 (Intrexon)
Microbial Mechanism of Disease in Obesity
Microbiota Associated with Obesity
Drug Development Strategies
Drugs in Development for Obesity
NM-504 (Microbiome Therapeutics)
NM-313 (Microbiome Therapeutics)
Fecal Microbiota Transplant (Seres Therapeutics)
Drug Development Strategies
Drugs in Development
NM-504 (Microbiome Therapeutics)
Bovin Colostrum (Immuron)
CP-001 (Caelus Health)
Seres Diabetes Program (Seres Therapeutics)
Microbiota Associated with Ulcerative Colitis and Crohn's Disease
Drugs in Development
EB-80818 (Enterome Biosciences)
EB-110 (Enterome Biosciences)
EB-120 (Enterome Biosciences)
SER-287 (Seres Therapeutics)
SGM-019 (Second Genome)
VT-301 (ViThera Pharmaceuticals)
RBX-8225 (Rebiotix)
AG-014 (Intrexon)
Market for Microbiome-based Drugs for Ulcerative Colitis
Market for Microbiome-Based Drugs for Crohn's Disease
Drug Development Strategies
Drugs in Development
VE-202 (Vedanta Biosciences)
SYN-004 (Synthetic Biologics)
SER-262/SER-109 (Seres Therapeutics)
Avidocin Proteins (AvidBiotics)
DAV-132 (DA Volterra)
CBM-588 (Osel Inc.)
RBX-2660 (Rebiotix)
Drug Development Strategies
Drugs in Development
RP-G28 (Ritter Pharmaceuticals)
Drug Development Strategies
Drugs in Development
C16-G2 (C3 Jian Inc.)
Drug Development Strategies
Drugs in Development
Acne
Rosacea
Atopic Dermatitis
Acne
Atopic Dermatitis
Rosacea
Drug Development Strategies
Drugs in Development
B-244 (AOBiome)
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Background
Drug Development Strategies
Drugs in Development
CHAPTER 5 HUMAN MICROBIOME-BASED DIAGNOSTICS MARKET
Microbiome Diagnostics: Overview
Microbiome Diagnostics: Technologies
Microbiome Diagnostics: Applications
Microbiome Diagnostics: Industry Collaborations
Market for Microbiome Diagnostics
Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease
Microbiome-based Diagnostics for Cancer
Microbiome Diagnostics for Women's Health
Microbiome Diagnostics for Dental caries
Overview
Companion Diagnostics in Development
IBD-210
IBD-110
Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease
Overview
Companion Diagnostics in Development
Oricol
Market for Microbiome-based Diagnostics for Cancer
Overview
Market for Microbiome Diagnostics for Women's Health
Overview
Microbiome-based Diagnostics in Development
Market for Microbiome-based Diagnostic for Dental Caries
CHAPTER 6 MICROBIOME INTELLECTUAL PROPERTY, INVESTMENTS AND COLLABORATIONS
Intellectual Property
Investments and Collaborations
Overview
Microbiome Patent Segments
Patents by Disease Area
Investments: Overview
Public Sector Investments
Private Sector Investments
Collaborations: overview
Microbiome Public Databases Overview
Clostridium Difficle Infection
Irritable Bowel Disorders
Diabetes and Obesity
Cancer
Lactose Intolerance
Hyperoxaluria
Recurrent Bacterial Vaginosis and Urinary tract infection
Dental Caries
Urea Cycle Disorders
Human Microbiome Initiative
MetaHIT Initiative
Venture Capital Investments
Initial Public Offerings
Industry Collaborations
Vedanta Biosciences/Johnson & Johnson
Seres Therapeutics/Nestle Health Science
Enterome Biosciences/Bristol-Meyers Squibb Co. (BMS)
Enterome Biosciences/Abbvie
Enterome Biosciences/Takeda
Synlogic Inc./AbbVie
Second Genome/Johnson & Johnson
Second Genome/Pfizer
Industry/Academic Collaborations
Enterome Biosciences/Mayo Clinic
Janssen Microbiome Institute/DayTwo Ltd. and Weizmann Institute
Vedanta Biosciences/NYU Langone Medical Center
Seres Therapeutics/Massachusetts General Hospital (MGH)
Seres Therapeutics/Mayo Clinic
Seres Therapeutics/University of Pennsylvania
Second Genome/The American Gut Project
Second Genome/King's College, London
Whole Biome/Mayo Clinic
American Gut Project Database
Integrative Human Microbiome Project Database
Human Oral Microbiome Database
CHAPTER 7 COMPANY PROFILES
4D PHARMA
AVIDBIOTICS INC.
AOBIOME LLC
AXIAL BIOTHERAPEUTICS
C3 JIAN INC.
CAELUS HEALTH
DA VOLTERRA
ELIGO BIOSCIENCES
ENTEROME BIOSCIENCES
EVELO BIOSCIENCES
EVOLVE BIOSYSTEMS
METABIOMICS
MICROBIOME THERAPEUTICS
ORIGIN SCIENCES LTD.
OSEL INC.
OXTHERA
RITTER PHARMACEUTICALS
REBIOTIX INC.
SECOND GENOME
SERES THERAPEUTICS
SYMBERIX
SYNLOGIC BIOTICS
SYNTHETIC BIOLOGICS
UBIOME INC.
VEDANTA BIOSCIENCES
VITHERA PHARMACEUTICALS
4D PHARMA PIPELINE
AvidBiotics Pipeline
Aobiome pipeline
C3 jian pipeline
Caelus Health Pipeline
Da Volterra Pipeline
Enterome Pipeline
Microbiome Therapeutics Pipeline
Osel Pipeline
Oxthera Pipeline
Ritter Pharmaceuticals Pipeline
Rebiotix Pipeline
Second Genome Pipeline
Seres Therapeutics Pipeline
Symberix Pipeline
Synlogic Pipeline
Synthetic Biologics Pipeline
Vedanta Biosciences Pipeline
ViThera Pharmaceuticals Pipeline
Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MICROBIOME OVERVIEW
Scientific Background
Human Microbiome in Health and Disease
Advances in Microbiome Research
Focus Areas for Microbiome-Based Drugs and Diagnostics
Microbiome-Based Drugs: Product Development Strategies
Current Challenges in Microbiome Drug Development
Human Microbiome Project
MetaHIT Consortium
Public Sector Initiatives in Microbiome Research
Key Goals of the Human Microbiome Project
Key Achievements of the Human Microbiome Project
Key Goals of MetaHIT Initiative
CHAPTER 4 HUMAN MICROBIOME-BASED DRUGS MARKET
Cancer
Obesity
Type 2 Diabetes
Ulcerative Colitis and Crohn's Disease
Clostridium Difficle Infection
Lactose Intolerance
Dental caries
Recurrent Bacterial Vaginosis and Urinary Tract Infection
Skin Diseases
Hyperoxaluria
Urea Cycle Disorder
Celiac Disease
Phenylketonuria
Non-alcoholic Steatohepatitis (NASH)
Background
Microbiome and Cancer
Microbiome-based Drugs for Cancer: Review of Drugs in Development
Market for Microbiome-based Drugs for Cancer
Background
Microbiome and Obesity
Microbiome-based Drugs for Obesity: Review of Drugs in Development
Market for Microbiome-based Drugs for Obesity
Background
Microbiome and Type 2 Diabetes
Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development
Market for Microbiome-based Drugs for Type 2 Diabetes
Background
Microbiome and Ulcerative Colitis/Crohn's Disease
Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs in Development
Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease
Background
Microbiome and Clostridium Difficle Infection
Microbiome-based Drugs for Clostridium Difficle Infection: Review of Drugs in Development
Market for Microbiome-based Drugs for Clostridium Difficle Infection
Background
Microbiome and Lactose Intolerance
Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development
Market for Microbiome-based Product for Lactose Intolerance
Background
Microbiome and Dental Caries
Microbiome-based Drugs for Dental Caries Review of Drugs in Development
Market for Microbiome-based Products for Dental Caries
Background
Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection
Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs in Development
Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI
Background
Microbiome and Skin Diseases
Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development
Market for Microbiome-based Drugs for Skin Diseases
Background
Microbiome and Hyperoxaluria
Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development
Market for Microbiome-based Products for Hyperoxaluria
Background
Microbiome and Urea Cycle Disorder
Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development
Market for Microbiome-Based Drugs for Urea Cycle Disorder
Background
Microbiome and Celiac Disease
Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development
Market for Microbiome-based Products for Celiac Disease
Background
Microbiome and Phenylketonuria
Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development
Market for Microbiome-based Products for Phenylketonuria
Background
Microbiome and Non-alcoholic Steatohepatitis
Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in Development
Market for Microbiome-based Products for Non-alcoholic Steatohepatitis
Microbiome-based Products for Hepatic Encephalopathy
Microbiome and Hepatic Encephalopathy
Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development
Market for Microbiome-based Drugs for Hepatic Encephalopathy
Drug Development Strategies
Microbiome-Based Drugs as Immune System Activators
Microbiome-Based Drugs as an Add-on to Immuno-Oncology Drugs
Microbiome-Based Drugs as Probiotic Mixtures
Microbiome-Based Drugs as Chemotherapy Adjuncts
Microbiome-Based Drugs in Development for Cancer
Micabodies (AvidBiotics)
Oncobiotics (Evelo Biosciences)
SER-155 (Seres Therapeutics)
Symberix Compound (Symberix)
MRX581 (4D Pharma)
AG-013 (Intrexon)
Microbial Mechanism of Disease in Obesity
Microbiota Associated with Obesity
Drug Development Strategies
Drugs in Development for Obesity
NM-504 (Microbiome Therapeutics)
NM-313 (Microbiome Therapeutics)
Fecal Microbiota Transplant (Seres Therapeutics)
Drug Development Strategies
Drugs in Development
NM-504 (Microbiome Therapeutics)
Bovin Colostrum (Immuron)
CP-001 (Caelus Health)
Seres Diabetes Program (Seres Therapeutics)
Microbiota Associated with Ulcerative Colitis and Crohn's Disease
Drugs in Development
EB-80818 (Enterome Biosciences)
EB-110 (Enterome Biosciences)
EB-120 (Enterome Biosciences)
SER-287 (Seres Therapeutics)
SGM-019 (Second Genome)
VT-301 (ViThera Pharmaceuticals)
RBX-8225 (Rebiotix)
AG-014 (Intrexon)
Market for Microbiome-based Drugs for Ulcerative Colitis
Market for Microbiome-Based Drugs for Crohn's Disease
Drug Development Strategies
Drugs in Development
VE-202 (Vedanta Biosciences)
SYN-004 (Synthetic Biologics)
SER-262/SER-109 (Seres Therapeutics)
Avidocin Proteins (AvidBiotics)
DAV-132 (DA Volterra)
CBM-588 (Osel Inc.)
RBX-2660 (Rebiotix)
Drug Development Strategies
Drugs in Development
RP-G28 (Ritter Pharmaceuticals)
Drug Development Strategies
Drugs in Development
C16-G2 (C3 Jian Inc.)
Drug Development Strategies
Drugs in Development
Acne
Rosacea
Atopic Dermatitis
Acne
Atopic Dermatitis
Rosacea
Drug Development Strategies
Drugs in Development
B-244 (AOBiome)
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Drug Development Strategies
Drugs in Development
Background
Drug Development Strategies
Drugs in Development
CHAPTER 5 HUMAN MICROBIOME-BASED DIAGNOSTICS MARKET
Microbiome Diagnostics: Overview
Microbiome Diagnostics: Technologies
Microbiome Diagnostics: Applications
Microbiome Diagnostics: Industry Collaborations
Market for Microbiome Diagnostics
Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease
Microbiome-based Diagnostics for Cancer
Microbiome Diagnostics for Women's Health
Microbiome Diagnostics for Dental caries
Overview
Companion Diagnostics in Development
IBD-210
IBD-110
Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease
Overview
Companion Diagnostics in Development
Oricol
Market for Microbiome-based Diagnostics for Cancer
Overview
Market for Microbiome Diagnostics for Women's Health
Overview
Microbiome-based Diagnostics in Development
Market for Microbiome-based Diagnostic for Dental Caries
CHAPTER 6 MICROBIOME INTELLECTUAL PROPERTY, INVESTMENTS AND COLLABORATIONS
Intellectual Property
Investments and Collaborations
Overview
Microbiome Patent Segments
Patents by Disease Area
Investments: Overview
Public Sector Investments
Private Sector Investments
Collaborations: overview
Microbiome Public Databases Overview
Clostridium Difficle Infection
Irritable Bowel Disorders
Diabetes and Obesity
Cancer
Lactose Intolerance
Hyperoxaluria
Recurrent Bacterial Vaginosis and Urinary tract infection
Dental Caries
Urea Cycle Disorders
Human Microbiome Initiative
MetaHIT Initiative
Venture Capital Investments
Initial Public Offerings
Industry Collaborations
Vedanta Biosciences/Johnson & Johnson
Seres Therapeutics/Nestle Health Science
Enterome Biosciences/Bristol-Meyers Squibb Co. (BMS)
Enterome Biosciences/Abbvie
Enterome Biosciences/Takeda
Synlogic Inc./AbbVie
Second Genome/Johnson & Johnson
Second Genome/Pfizer
Industry/Academic Collaborations
Enterome Biosciences/Mayo Clinic
Janssen Microbiome Institute/DayTwo Ltd. and Weizmann Institute
Vedanta Biosciences/NYU Langone Medical Center
Seres Therapeutics/Massachusetts General Hospital (MGH)
Seres Therapeutics/Mayo Clinic
Seres Therapeutics/University of Pennsylvania
Second Genome/The American Gut Project
Second Genome/King's College, London
Whole Biome/Mayo Clinic
American Gut Project Database
Integrative Human Microbiome Project Database
Human Oral Microbiome Database
CHAPTER 7 COMPANY PROFILES
4D PHARMA
AVIDBIOTICS INC.
AOBIOME LLC
AXIAL BIOTHERAPEUTICS
C3 JIAN INC.
CAELUS HEALTH
DA VOLTERRA
ELIGO BIOSCIENCES
ENTEROME BIOSCIENCES
EVELO BIOSCIENCES
EVOLVE BIOSYSTEMS
METABIOMICS
MICROBIOME THERAPEUTICS
ORIGIN SCIENCES LTD.
OSEL INC.
OXTHERA
RITTER PHARMACEUTICALS
REBIOTIX INC.
SECOND GENOME
SERES THERAPEUTICS
SYMBERIX
SYNLOGIC BIOTICS
SYNTHETIC BIOLOGICS
UBIOME INC.
VEDANTA BIOSCIENCES
VITHERA PHARMACEUTICALS
4D PHARMA PIPELINE
AvidBiotics Pipeline
Aobiome pipeline
C3 jian pipeline
Caelus Health Pipeline
Da Volterra Pipeline
Enterome Pipeline
Microbiome Therapeutics Pipeline
Osel Pipeline
Oxthera Pipeline
Ritter Pharmaceuticals Pipeline
Rebiotix Pipeline
Second Genome Pipeline
Seres Therapeutics Pipeline
Symberix Pipeline
Synlogic Pipeline
Synthetic Biologics Pipeline
Vedanta Biosciences Pipeline
ViThera Pharmaceuticals Pipeline
LIST OF TABLES
Table 1 Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024
Table 2 Focus Disease Areas for Microbiome Research
Table 3 Microbiome Drug Development Approaches
Table 4 U.S. Prevalence of Cancer, through 2024
Table 5 Microbiota Associated with Cancers
Table 6 Microbiome-based Drugs in Development for Cancer
Table 7 U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018-2024
Table 8 U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024
Table 9 U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024
Table 10 Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024
Table 11 U.S. Prevalence of Obesity, through 2024
Table 12 Microbiota Associated with Obesity
Table 13 Microbiome-based Drugs in Development for Obesity
Table 14 U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024
Table 15 U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through2024
Table 16 U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024
Table 17 U.S. Prevalence of Type 2 Diabetes, through 2024
Table 18 Microbiota Associated with Type 2 Diabetes
Table 19 Microbiome-based Drugs in Development for Type 2 Diabetes
Table 20 U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024
Table 21 U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024
Table 22 U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024
Table 23 Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024
Table 24 U.S. Prevalence of Ulcerative Colitis and Crohn's Disease, through 2024
Table 25 Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn’s Disease
Table 26 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024
Table 27 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease, through 2024
Table 28 U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018-2024
Table 29 U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024
Table 30 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024
Table 31 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024
Table 32 U.S. Market Shares of Microbiome-based Drugs for Crohn's Disease, by Company, 2018-2024
Table 33 U.S. Patient Volumes for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024
Table 34 U.S. Market for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024
Table 35 Rest of the World Market for Microbiome-based Drugs for Crohn's Disease, by Country/Region, through 2024
Table 36 U.S. Prevalence of Clostridium Difficle Infection, through 2024
Table 37 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 38 U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018-2024
Table 39 U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024
Table 40 U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024
Table 41 Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024
Table 42 U.S. Prevalence of Lactose Intolerance, through 2024
Table 43 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 44 U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018-2024
Table 45 U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024
Table 46 U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024
Table 47 Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024
Table 48 U.S. Prevalence of Dental Caries, through 2024
Table 49 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 50 U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018-2024
Table 51 U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024
Table 52 U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024
Table 53 Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024
Table 54 U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024
Table 55 Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection
Table 56 U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018-2024
Table 57 U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024
Table 58 U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024
Table 59 Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024
Table 60 U.S. Prevalence of Skin Diseases, through 2024
Table 61 Microbiome-based Drugs in Development for Skin Diseases
Table 62 U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018-2024
Table 63 U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024
Table 64 U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024
Table 65 Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024
Table 66 U.S. Prevalence of Hyperoxaluria, through 2024
Table 67 Microbiome-based Drugs in Development for Skin Diseases
Table 68 U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by Company, 2018-2024
Table 69 U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024
Table 70 U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024
Table 71 Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024
Table 72 U.S. Prevalence of Urea Cycle Disorder, through 2024
Table 73 Microbiome-based Drugs in Development for Urea Cycle Disorder
Table 74 U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder,by Company, 2018-2024
Table 75 U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024
Table 76 U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024
Table 77 U.S. Prevalence of Celiac Disease, through 2024
Table 78 Microbiota Associated with Celiac Disease
Table 79 Microbiome-based Drugs in Development for Celiac Disease
Table 80 U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018-2024
Table 81 U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024
Table 82 U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024
Table 83 U.S. Prevalence of Phenylketonuria, through 2024
Table 84 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024
Table 85 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024
Table 86 U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024
Table 87 U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024
Table 88 Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024
Table 89 U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024
Table 90 Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis
Table 91 U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018-2024
Table 92 U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024
Table 93 U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024
Table 94 Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024
Table 95 U.S. Prevalence of Hepatic Encephalopathy, through 2024
Table 96 Microbiome-based Drugs in Development for Hepatic Encephalopathy
Table 97 U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018-2024
Table 98 U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024
Table 99 U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024
Table 100 Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024
Table 101 Comparison of Microbiome Sequencing Technologies
Table 102 U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024
Table 103 Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024
Table 104 U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, 2018-2024
Table 105 U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024
Table 106 U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024
Table 107 U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 108 U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018-2024
Table 109 U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 110 U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 111 U.S. Prevalence of Microbiome-based Diagnostics for Women's Health, through 2024
Table 112 U.S. Market Shares of Microbiome-based Diagnostics for Women’s Health, by Company, 2018-2024
Table 113 U.S. Assay Volumes for Microbiome-based Diagnostics for Women’s Health, through 2024
Table 114 U.S. Market for Microbiome-based Diagnostics for Women's Health, through 2024
Table 115 U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018-2024
Table 116 U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024
Table 117 U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024
Table 118 U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficle Infection
Table 119 U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome
Table 120 U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity
Table 121 U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer
Table 122 U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance
Table 123 U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria
Table 124 U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urniary Tract Infection
Table 125 U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries
Table 126 U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders
Table 127 Venture Capital Investments in Microbiome Start-Ups
Table 128 Initial Public Offerings by Microbiome-Based Companies
Table 129 Industry collaborations in Microbiome-based Companies
Table 130 4D Pharma Pipeline
Table 131 Avidbiotics Pipeline
Table 132 AObiome Pipeline
Table 133 C3 Jian Pipeline
Table 134 Caelus Pipeline
Table 135 Da Volterra Pipeline
Table 136 Enterome Pipeline
Table 137 Microbiome Therapeutics Pipeline
Table 138 Osel Pipeline
Table 139 Oxthera Pipeline
Table 140 Oxthera Pipeline
Table 141 Rebiotix Pipeline
Table 142 Second Genome Pipeline
Table 143 Seres Therapeutics Pipeline
Table 144 Synlogic Pipeline
Table 145 Synthetic Biologics Pipeline
Table 146 Vedanta Biosciences Pipeline
Table 147 ViThera Pharmaceuticals Pipeline
Table 1 Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024
Table 2 Focus Disease Areas for Microbiome Research
Table 3 Microbiome Drug Development Approaches
Table 4 U.S. Prevalence of Cancer, through 2024
Table 5 Microbiota Associated with Cancers
Table 6 Microbiome-based Drugs in Development for Cancer
Table 7 U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018-2024
Table 8 U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024
Table 9 U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024
Table 10 Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024
Table 11 U.S. Prevalence of Obesity, through 2024
Table 12 Microbiota Associated with Obesity
Table 13 Microbiome-based Drugs in Development for Obesity
Table 14 U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024
Table 15 U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through2024
Table 16 U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024
Table 17 U.S. Prevalence of Type 2 Diabetes, through 2024
Table 18 Microbiota Associated with Type 2 Diabetes
Table 19 Microbiome-based Drugs in Development for Type 2 Diabetes
Table 20 U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024
Table 21 U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024
Table 22 U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024
Table 23 Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024
Table 24 U.S. Prevalence of Ulcerative Colitis and Crohn's Disease, through 2024
Table 25 Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn’s Disease
Table 26 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024
Table 27 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease, through 2024
Table 28 U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018-2024
Table 29 U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024
Table 30 U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024
Table 31 Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024
Table 32 U.S. Market Shares of Microbiome-based Drugs for Crohn's Disease, by Company, 2018-2024
Table 33 U.S. Patient Volumes for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024
Table 34 U.S. Market for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024
Table 35 Rest of the World Market for Microbiome-based Drugs for Crohn's Disease, by Country/Region, through 2024
Table 36 U.S. Prevalence of Clostridium Difficle Infection, through 2024
Table 37 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 38 U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018-2024
Table 39 U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024
Table 40 U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024
Table 41 Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024
Table 42 U.S. Prevalence of Lactose Intolerance, through 2024
Table 43 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 44 U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018-2024
Table 45 U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024
Table 46 U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024
Table 47 Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024
Table 48 U.S. Prevalence of Dental Caries, through 2024
Table 49 Microbiome-based Drugs in Development for Clostridium Difficle Infection
Table 50 U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018-2024
Table 51 U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024
Table 52 U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024
Table 53 Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024
Table 54 U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024
Table 55 Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection
Table 56 U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018-2024
Table 57 U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024
Table 58 U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024
Table 59 Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024
Table 60 U.S. Prevalence of Skin Diseases, through 2024
Table 61 Microbiome-based Drugs in Development for Skin Diseases
Table 62 U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018-2024
Table 63 U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024
Table 64 U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024
Table 65 Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024
Table 66 U.S. Prevalence of Hyperoxaluria, through 2024
Table 67 Microbiome-based Drugs in Development for Skin Diseases
Table 68 U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by Company, 2018-2024
Table 69 U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024
Table 70 U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024
Table 71 Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024
Table 72 U.S. Prevalence of Urea Cycle Disorder, through 2024
Table 73 Microbiome-based Drugs in Development for Urea Cycle Disorder
Table 74 U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder,by Company, 2018-2024
Table 75 U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024
Table 76 U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024
Table 77 U.S. Prevalence of Celiac Disease, through 2024
Table 78 Microbiota Associated with Celiac Disease
Table 79 Microbiome-based Drugs in Development for Celiac Disease
Table 80 U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018-2024
Table 81 U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024
Table 82 U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024
Table 83 U.S. Prevalence of Phenylketonuria, through 2024
Table 84 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024
Table 85 U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018-2024
Table 86 U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024
Table 87 U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024
Table 88 Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024
Table 89 U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024
Table 90 Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis
Table 91 U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018-2024
Table 92 U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024
Table 93 U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024
Table 94 Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024
Table 95 U.S. Prevalence of Hepatic Encephalopathy, through 2024
Table 96 Microbiome-based Drugs in Development for Hepatic Encephalopathy
Table 97 U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018-2024
Table 98 U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024
Table 99 U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024
Table 100 Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024
Table 101 Comparison of Microbiome Sequencing Technologies
Table 102 U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024
Table 103 Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024
Table 104 U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, 2018-2024
Table 105 U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024
Table 106 U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024
Table 107 U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 108 U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018-2024
Table 109 U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 110 U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024
Table 111 U.S. Prevalence of Microbiome-based Diagnostics for Women's Health, through 2024
Table 112 U.S. Market Shares of Microbiome-based Diagnostics for Women’s Health, by Company, 2018-2024
Table 113 U.S. Assay Volumes for Microbiome-based Diagnostics for Women’s Health, through 2024
Table 114 U.S. Market for Microbiome-based Diagnostics for Women's Health, through 2024
Table 115 U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018-2024
Table 116 U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024
Table 117 U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024
Table 118 U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficle Infection
Table 119 U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome
Table 120 U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity
Table 121 U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer
Table 122 U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance
Table 123 U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria
Table 124 U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urniary Tract Infection
Table 125 U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries
Table 126 U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders
Table 127 Venture Capital Investments in Microbiome Start-Ups
Table 128 Initial Public Offerings by Microbiome-Based Companies
Table 129 Industry collaborations in Microbiome-based Companies
Table 130 4D Pharma Pipeline
Table 131 Avidbiotics Pipeline
Table 132 AObiome Pipeline
Table 133 C3 Jian Pipeline
Table 134 Caelus Pipeline
Table 135 Da Volterra Pipeline
Table 136 Enterome Pipeline
Table 137 Microbiome Therapeutics Pipeline
Table 138 Osel Pipeline
Table 139 Oxthera Pipeline
Table 140 Oxthera Pipeline
Table 141 Rebiotix Pipeline
Table 142 Second Genome Pipeline
Table 143 Seres Therapeutics Pipeline
Table 144 Synlogic Pipeline
Table 145 Synthetic Biologics Pipeline
Table 146 Vedanta Biosciences Pipeline
Table 147 ViThera Pharmaceuticals Pipeline
LIST OF FIGURES
Figure 1 Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024
Figure 2 Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024
Figure 3 Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024
Figure 4 Human Microbiome Based Drugs, Pipeline Projects, 2016
Figure 5 Microbes Involved in Healthy Facial Skin
Figure 6 Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016
Figure 1 Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024
Figure 2 Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024
Figure 3 Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024
Figure 4 Human Microbiome Based Drugs, Pipeline Projects, 2016
Figure 5 Microbes Involved in Healthy Facial Skin
Figure 6 Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016
